The vision of Numeric Biotech is to build an innovative portfolio of first-in-class treatments that target multiple mechanisms of age related diseases including cancer. Our programs are based on cutting-edge research performed by Erasmus University Medical Center Rotterdam, The Netherlands. Through linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Numeric Biotech will drive its portfolio of ground-breaking therapies from laboratory to clinic through various collaborations with leading research institutes and clinics which will give the company a firm basis in the new research paradigm of aging and age related diseases.
Numeric Biotech have a highly experienced and dedicated leadership team with an outstanding track record of discovering and developing innovative medicines. The Numeric Biotech team members all have a longstanding history of successful drug launches and commercial success, both in a smaller biotechnology environment as as well as larger blue chip pharmaceutical companies.
Chronological age represents the single greatest risk factor for human disease. Cellular senescence, which is a permanent state of cell cycle arrest induced by cellular inflammation and stress, has recently emerged as a fundamental component of the mechanism of aging that contributes (by secretion of inflammatory molecules) to diseases of later life, including cancer, atherosclerosis and osteoarthritis.
Numeric Biotech develops therapeutic compounds that selectively eliminate senescent cells (SNC’s). These therapeutic compounds were tested in various ex-vivo and animal models that demonstrated reversal of the underlying disease process, which may have a preventative effect regarding oncogenesis and the inception of chronic degenerative target organ diseases.
Striking pre-clinical in-vivo results were published in peer reviewed scientific journals regarding disease modifying effects in the following indications:
- Treatment refractory forms of Metastatic Melanoma, Breast Cancer and Glioblastoma Multiforme
- Chronic Kidney Disease
- Secondary effects of systemic chemotherapy
Numeric Biotech has generated a pipeline of proprietary selective senolytic lead compounds that are able to target and eradicate or cells whose status is undermined by senescent processes. Numeric Biotech is poised to initiate the first of a series of clinical programs by 2019.
Hans van Berkum served as CEO (and was also member of the Board of Directors) of Virosome Biologicals BV. from founding until the company was acquired by Norwood Immunology (now Mymetics Corp.). Prior to that he held several senior executive positions: being responsible for worldwide regulatory affairs of major pharmaceutical companies and was international medical director of US based pharmaceutical company. He was also a European general manager of a main biotech company, running the first approval process of lead compounds and successful introduction and marketing. During his career he was actively involved in various M&A and investment projects. He worked for companies such as Astra (now AstraZeneca), Hoffmann- La Roche, and Genzyme (now Sanofi) in several executive management positions.
Hans obtained a PharmD degree specializing in neuroscience from the University of Leiden (The Netherlands) and holds an International Master of Business Administration from the Dutch School of Management in Utrecht (The Netherlands).
Over the past decade Piet Bruijnzeel worked as Senior Director Early Clinical Development for Sandoz, Organon, Schering Plough, Merck, AstraZeneca (UK and Sweden) and finally at Polyphor (Switzerland). In this role he was the clinical lead of teams bringing various new drugs very successfully from pre-clinical phases to First into Man and Proof of Concept up to market launch. Before that he had his own company that aimed to develop a monoclonal antibody as an ingredient of an anti-ageing cream. Piet also had different leading roles at CRO's and was a staff member of the Department of Pulmonary Disease at the University of Utrecht. His main areas of interest are: chronic inflammation and ageing. Piet has been author of more than 120 peer reviewed papers.
Piet obtained his PhD in Clinical Immunology at the University Medical Center in Utrecht (The Netherlands) and an MD at the same institution. He also attended a post graduate course in Pharmaceutical Medicine.
Lars Bastiaanse has over 25 years of experience in clinical development, project management and general management in the pharmaceutical, biotech, and CRO/Consultancy business. He was with Johnson & Johnson in positions of increasing seniority in the product development. Amongst other responsibilities, Lars was Global Project Leader at J&J for the development of immunology products currently on the market such as Intelence, and Edurant. In addition, Lars was CEO for Kinesis Pharma, 3D-PharmXchange, and Cardialysis. Lars is also the General Manager of PMD Consulting BV, an independent life science consultancy organization.
Lars obtained a MSc degree in pharmacy and completed his PhD degree in Medicinal Sciences (cardio biochemistry) at the Leiden University Medical Centre (The Netherlands).
Joost van Bree worked in senior management positions and C-suite positions with responsibility for drug development, strategic development, regulatory affairs, business development and having raised private as well as public financing. He has gained extensive experience in strategic and operational hands-on management and leadership positions and served in executive as well as non-executive director board positions at several public and private Life Science companies, amongst which were Sandoz/Novartis, Teva, Pharming, Pepscan and Immunovo.
Joost obtained an MSc and PharmD, after which he specialized and did his PhD in Clinical Pharmacology, both at the Leiden University Medical Centre (The Netherlands).
Brian Eisenburger brings over 27 years of international operations and project management experience. Having worked in Europe, Japan and the US he gained expertise working in various leadership roles for various bio-pharmaceutical companies but also at CMO/CRO companies. As director business development he was responsible for out-licensing activities at a number of biotech companies, such as Pharming, Algonomics, DSM, etc. He was responsible for various successful venture capital fundraising deals and sales & marketing activities. He set up a branch office in the pharmaceutical industry in Japan for an European CRO organisation, worked as senior production project leader in the US for a worldwide pharmaceutical & food ingredient company. His background education is master of business economics (Erasmus University Medical Center Rotterdam) and engineering (Technical University in Delft, The Netherlands).
Patricia Ringeling is a qualified Dutch and European Patent Attorney. Patricia has more than 20 years of extensive patent experience as a patent attorney in various settings. Previously, Patricia was in-house patent attorney at Gist-Brocades/DSM, Director Intellectual Property at Pharming, and patent attorney at private practice Nederlandsch Octrooibureau (NLO). She works at the independent patent practice Enelex Innovation BV in Delft, which she founded in 2006 to provide patent support to start-ups and innovative SMEs in the life sciences. Patricia is a member of the Institute of Dutch Patent Attorneys, the Institute of Professional Representatives before the European Patent Office, Licensing Executive Society (LES) and Public interest Intellectual Property Advisors (PIIPA), a global non-profit resource for public interest organizations in developing countries seeking expertise in intellectual property.
Patricia studied chemistry with minors immunology and oncology, at the University of Amsterdam and holds a PhD from the Erasmus University Medical Center (The Netherlands). She was as a postdoc researcher in the field of iron metabolism at the University of East Anglia, Norwich UK, and a lecturer in bioinorganic chemistry. Patricia holds a Certificate in Intellectual Property from Queen Mary, University of London.
Numeric Biotech further expands its executive team with additional biotech industry veterans
Rotterdam, The Netherlands, June 5, 2018 - Numeric Biotech BV, a privately held biotechnology company creating therapeutics to cure and prevent age-related diseases, announces recent additions to its executive team.
Lars Bastiaanse will join Numeric as Chief Development Officer. Lars has over 25 years of experience in clinical development, project management and general management in pharmaceutical, biotech, but also CRO/Consultancy companies. He was responsible for various development phases for many biotech products. At Johnson & Johnson for instance, Lars was incremental for the development of immunology products currently on the market such as Intelence, and Edurant. Lars obtained a MSc degree in pharmacy and completed his PhD degree in Medicinal Sciences at the Leiden University Medical Centre (The Netherlands).
Joining as VP Regulatory Affairs and Quality, Joost van Bree has over 20-years industry experience in successfully bringing conventional and biotech drugs through development and regulatory approval. He has worked in various international management positions in the fields of drug development, clinical pharmacology, and regulatory affairs with Sandoz (now Novartis) in Switzerland, Teva, Immunovo and Pepscan. At Pharming he held the position of VP Clinical Development and Regulatory Affairs. In addition, he brings the experience of raising funds of over Euro 100 Million with venture capital financing as well as a successful IPO and secondary listing. Joost holds an MSc in Pharmacy and a PhD in Clinical Pharmacology, both from Leiden University (The Netherlands).
Patricia Ringeling, will join Numeric as VP Intellectual Property. Patricia has over 20 years of experience in patent practice including litigation, as a qualified Dutch and European Patent Attorney. She worked at companies such as the Dutch Patent office (NLO), DSM and Pharming but also various start-up companies in the life science industry. Patricia studied chemistry with minors immunology and oncology, at the University of Amsterdam, holds a PhD from the Erasmus University Medical Center Rotterdam (The Netherlands) and a Certificate in Intellectual Property from Queen Mary, University of London.
"We are very happy to be able to attract this talent and relevant experience that matches the level of potential of Numeric's mission to attack the age-related diseases with our first lead oncology indication," said Hans van Berkum, Numeric CEO.
Numeric Biotech receives first investment from UNIIQ for the development of anti-senescence drug compounds
Rotterdam, 25 April 2018 – Numeric Biotech, an Erasmus MC Spinoff company developing compounds against cell senescence, is receiving €300,000 from the UNIIQ investment fund and Erasmus MC. Using this investment, Numeric Biotech can make an important step forward in the development of its lead drug compounds. The investment was announced by Liduina Hammer, Fund Manager UNIIQ and Thijs Spigt, Director Erasmus MC TTO, during the UNIIQ Spring Live event in Leiden.
Senescence and cancer therapy
In the majority of cases, damaged human cells are cleared by the body’s own defence mechanisms. In some cases, however, such cells will remain in the body. These cells, called senescent cells, also play an important role in the aging process of the human body. Numeric Biotech, in collaboration with Erasmus MC, has shown that their lead drug compound is able to clear these senescent cells effectively in mice.
A number of aging diseases might be able to be treated using the technology of Numeric Biotech, but the company will first focus on oncological indications. “We believe that this important technology will contribute to a better understanding of clearing senescent cells from the human body”, says Hans van Berkum, co-founder and CEO of Numeric Biotech, “the support from UNIIQ allows us to further study age-related diseases and in particular the effect of our drug compounds for treatment of certain cancers.”
UNIIQ Proof of Concept investment
“We are very enthusiastic about the opportunities for the technology developed at Numeric Biotech”, says Liduina Hammer, Fund manager at UNIIQ. “The field of senescence is rapidly developing and pre-clinical results have shown great potential for future treatments. We are confident that Numeric Biotech, in collaboration with excellent academic institutions such as Erasmus MC, can further improve patient treatment. UNIIQ focusses on investments with major potential impact and with this investment we have clearly found such potential”.
With the investment by UNIIQ and Erasmus MC, Numeric Biotech will be able to further develop their drug compounds in order to perform additional pre-clinical experiments, necessary for the product to enter clinical trials. Numeric Biotech has a worldwide exclusive license from Erasmus MC covering the substance FOXO4-DRI including a wide range of variations.
- Baar M.P., Brandt R.M.C., Putavet D.A., Klein J.D.D., Derks K.W.J., Bourgeois B.R.M., Stryeck S., Rijksen Y., van Willigenburg H., Feijtel H.A., van der Pluijm I., Essers J., van Cappellen W.A., van IJcken W.F., Houtsmuller A.B., Pothof J., de Bruin R.W.F., Madl T., Hoeijmakers J.H.J., Campisi J., de Keizer P.J.L.”Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging” Cell. (2017), March 23; 169 (1): 132-47
- de Keizer P., Burgering B, Dansen TB. “FOXO as a sensor, mediator and regulator of redox signaling” Antioxid. Redox Signal. 2011 Mar 15;14(6):1093-106.
- de Keizer P.L., Laberge R.M., Campisi J. “p53: Pro-aging or pro-longevity?” Aging (Albany NY). (2010) Jul;2(7):377-9.
- de Keizer P.L.J., Riedl-Polderman P.E., Szypowska A.A., Packer L.M., van den Broek N.J.F., Dansen T.B., Marais R., Brenkman A.B., Burgering,B.M.T. "Activation of FOXO transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence" Cancer Res. (2010) Nov 1;70(21):8526-36.
- Brenkman A.B., van den Broek N.J.F., de Keizer P.L.J., van Gent D., Burgering B.M.T. “The DNA damage repair protein Ku70 interacts with FOXO4 to coordinate a conserved cellular stress response.” FASEB J. (2010) Nov;24(11):4271-80.
- de Keizer P.L., Brenkman A.B., van den Broek N.J., van der Groep P., van Diest P.J., van der Horst A., Smits A.M., Burgering B.M. "The peptidyl-isomerase Pin1 regulates p27kip1 expression through inhibition of Forkhead box O tumor suppressors." Cancer Res. 68(18), 7597 (2008).
At Numeric Biotech you will have the opportunity to contribute and to develop your skills and experience in a dynamic, fast moving and multicultural environment. This means we have a passionate team that is dedicated to make a huge difference in the new research and development area of aging related diseases. As an innovative company, Numeric Biotech is continuously seeking for ambitious colleagues with an academic and/or industrial background that are passionate about our mission. We embrace diversity, be it age, gender, ethnicity, nationality, religion, or working and thinking style.